IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTORS: Oppermann et al.

Assignee: Stryker Corporation

APPLICATION NO.: 09/754,831

PATENT NO.: 7,078,221

FILING DATE .: January 3, 2001

ISSUE DATE: July 18, 2006

TITLE: Nucleic Acid Molecules Encoding Osteogenic Proteins

Mail Stop Petition Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

PETITION PURSUANT TO 37 C.F.R. § 1.78(a)(3) TO CORRECT A DOMESTIC PRIORITY CLAIM PURSUANT TO 35 U.S.C. § 120

Sir:

This is a petition pursuant to 37 C.F.R. § 1.78(a)(3) to correct the domestic priority claim pursuant to 35 U.S.C. § 120 of the above-identified application. The petition fee of \$1410.00 due under 37 C.F.R. § 1.17(t) has been charged to Attorney's Deposit Account No. 50-1721 at the time of filing this paper via EFS-Web. Applicants believe that this fee is sufficient for consideration of this petition; however, if Applicants are in error, please charge any additional fee(s) necessary to Attorney's Deposit Account No. 50-1721.

The following domestic priority claim under 35 U.S.C. § 120 has been recognized by the U.S. Patent and Trademark Office (USPTO) for the above-identified patent application:

This application is continuation of U.S. Application No. 08/375,901, filed January 20, 1995, now U.S. Patent No. 6,261,835, which is a division of U.S. Application No. 08/145,812, filed November 1, 1993, now U.S. Patent No. 5,750,651, which is a division of U.S. Application No. 07/995,345, filed December 22, 1992, now U.S. Patent No. 5,258,494, which is a division of U.S. Application No. 07/315,342, filed February 23, 1989, now U.S. Patent No. 5,011,691, which is a continuation-in-part of U.S. Application No. 07/323,630, filed August 15, 1988, now abandoned, which is a continuation-in-part of U.S. Application No. 07/315,45,6161 August 15, 1988, now U.S. Patent No. 4,968,590.

Petition to Correct a Domestic Priority Claim Under 37 C.F.R. § 1.78(a)(3) Submitted November 4, 2008 Application No. 190754,831 Patent No.: 7,078,221 Attorney Docket No.: STK-008CN Page 2 of 3

That this priority claim has been recognized by the USPTO is evidenced by its publication on the front page of U.S Patent No. 7,078,221, the patent number for this application, a copy of which is attached as "Exhibit A."

Applicants have discovered that this priority claim, while correct, is incomplete.

Applicants submit that the correct domestic priority is as follows:

This application is a continuation of U.S. Application No. 08/375,901, filed January 20, 1995, now U.S. Patent No. 6,261,835, which is a division of U.S. Application No. 08/145,812, filed November 1, 1993, now U.S. Patent No. 5,750,651, which is a division of U.S. Application No. 07/995,345, filed December 22, 1992, now U.S. Patent No. 5,258,494, which is a continuation of U.S. Application No. 07/621,988, filed December 4, 1990, now abandoned, which is a division of U.S. Application No. 07/315,342, filed February 23, 1989, now U.S. Patent No. 5,011,691, which is a continuation-in-part of U.S. Application No. 07/232,630, filed August 15, 1988, now abandoned, which is a continuation-in-part of U.S. Application No. 07/179,406, filed April 8, 1988, now U.S. Patent No. 4,968,590.

In other words, Applicants inadvertently omitted the reference to U.S. Application No. 07/621,988 from the domestic priority claim under 35 U.S.C. § 120 submitted in the instant application. U.S. Application No. 07/621,988 was abandoned in favor of U.S. Application No. 07/995,345, which was a file wrapper continuation of 07/621,988. This is evidenced by the bibliographic data for U.S. Application No. 07/621,988, available in PAIR, a printout of which is attached as "Exhibit B" and by the continuity data for U.S. Application No. 07/995,345, available in PAIR, a printout of which is attached as "Exhibit C."

Applicants concurrently submit with this Petition a Request for Certificate of Correction under 35 U.S.C. § 254 and 37 C.F.R. § 1.323 to amend the "Related U.S. Application Data" section on the front page of the patent and to amend the "Cross Reference to Related Applications" section of the specification to indicate the relationship of the instant U.S. patent application to the prior filed applications as required under 37 C.F.R. § 1.78(a)(3)(i).

As previously stated, Applicants have charged the \$1410.00 petition fee under 37 C.F.R. § 1.17(t) as required by 37 C.F.R. § 1.78(a)(3)(ii) for acceptance of an unintentionally delayed Petition to Correct a Domestic Priority Claim Under 37 C.F.R. § 1.78(a)(3) Submitted November 4, 2008 Application No.: 09/754,831 Patent No.: 7,078,221 Attorney Docket No.: STK-008CN Pages 3 of 3

claim for priority to Attorney's Deposit Account No. 50-1721 at the time of filing this paper via EFS-Web.

Further, Applicants submit that the entire delay between the date the claim was due under 37 C.F.R. § 1.78(a)(2)(ii) and the date the claim was filed was unintentional. Applicants therefore respectfully request that this petition to amend the domestic priority claim of the instant application under 35 U.S.C. § 120 be granted.

The Examiner of this petition is invited to contact the undersigned attorney if a telephone conversation would be helpful in resolving this issue.

Respectfully submitted,

Date: November 4, 2008 Limited Recognition No.: L0363

Ediffica Recognition 140.. 1205

Tel. No.: (617) 261-3237 Fax No.: (617) 261-3175

BOS-1249907 v1

/Crystal A. Komm/ Crystal A. Komm Attorney for the Applicant K&L Gates LLP State Street Financial Center One Lincoln Street

Boston, Massachusetts 02111

(12) United States Patent Oppermann et al.

(10) Patent No.:

US 7,078,221 B2 (45) Date of Patent: *Jul. 18, 2006

(54) NUCLEIC ACID MOLECULES ENCODING OSTEOGENIC PROTEINS

- (75) Inventors: Hermann Oppermann, Medway, MA (US); Thangavel Kuberasampath, Medway, MA (US); David C. Rueger, West Roxbury, MA (US); Engin Ozkaynak, Milford, MA (US)
- (73) Assignee: Stryker Biotech, Hopkinton, MA (US)
- (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 662 days.

This patent is subject to a terminal disclaimer.

- (21) Appl. No.: 09/754,831
- (22) Filed: Jan. 3, 2001
- (65)Prior Publication Data
 - US 2003/0228345 A1 Dec. 11, 2003

Related U.S. Application Data

(60) Continuation of application No. 08/375,901, filed on Jan. 20, 1995, now Pat. No. 6,261,835, which is a division of application No. 08/145,812, filed on Nov. 1, 1993, now Pat, No. 5,750,651, which is a division of application No. 07/995,345, filed on Dec. 22, 1992, now Pat. No. 5,258,494, which is a division of application No. 07/315,342, filed on Feb. 23, 1989, now Pat. No. 5,011,691, which is a continuation-inpart of application No. 07/232,630, filed on Aug. 15, 1988, now abandoned, which is a continuation-in-part of application No. 07/179,406, filed on Apr. 8, 1988, now Pat. No. 4,968,590.



- (2006.01) C12N 1/19 (2006.01)C12N 5/16 (2006.01) C12N 15/12 (2006.01)
- 435/252.3; 435/254.11; (52) U.S. Cl. 435/325; 536/23.1; 536/23.5
- (58) Field of Classification Search . 536/231. 536/235; 435/252.3, 254.11, 325 See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

4,294,753	Α		Urist 530/395
4.394,370	A	7/1983	Jefferies 424/15
4,434,094	Α	2/1984	Seyedin et al 530/416
4,455,256	A	6/1984	Urist 530/350
4,563,350		1/1986	Nathan et al 424/95
4,563,489	Α	1/1986	Urist 524/21
4,774,322	A	9/1988	Seyedin et al 530/353
4,795,804	A	1/1989	Urist 530/350
4,804,744	A	2/1989	Sen 530/350
4,810,691	A		Seyedin et al 514/2
4,843,063	A	6/1989	Sevedin et al 514/2
, .			•

4,877,864	A		10/1989	Wang et al 530/324
5,013,649	Α		5/1991	Wang et al 435/69.1
5,106,626	Α		4/1992	Parsons et al 424/423
5,106,748	Α		4/1992	Wozney et al 435/252.3
5,108,922	Α		4/1992	Wang et al 435/240
5,116,738	Α		5/1992	Wang et al 435/69.1
5,141,905	A		8/1992	Rosen et al 435/69.1
5,154,931	Α		10/1992	Kruger et al.
5,166,058	Α		11/1992	Wang et al 435/69.1
5,187,076	A		2/1993	Wozney et al 435/69.1
5,250,302	A		10/1993	Oppermann et al 424/422
5,366,875	Α		11/1994	Wozney et al.
5,585,237	A	*1	12/1996	Oppermann et al 435/6
5,614,385	Α	*	3/1997	Oppermann et al 435/69.4
5,652,118	A	*	7/1997	Ozkaynak et al 435/69.1
5,670,336		٠	9/1997	Oppermann et al 435/69.1
5,712,119	Α	٠	1/1998	Oppermann et al 435/69.4
5,863,758	A	٠	1/1999	Oppermann et al 435/69.1
6,071,695	Α	*	6/2000	Ozkaynak et al 435/6
6,261,835	BI	*	7/2001	Oppermann et al 435/320.1

FOREIGN PATENT DOCUMENTS

0128041	12/1984
0148155	7/1985
0169016	1/1986
0182483	5/1986
0212474	3/1987
85/05274	12/1985
86/00526	1/1986
88/00205	1/1988
89/09605	10/1989
89/10409	11/1989
90/03733	4/1990
	10/1990
91/02744	3/1991
	0148155 0169016 0182483 0212474 85/05274 86/00526 88/00205 89/09605 89/10409 90/03733 90/11366

(Continued)

OTHER PUBLICATIONS

Canalis et al., "Stimulation of DNA and Collagen Synthesis by Antologous Growth Factor in Cultured Fetal Rat Calvaria," Science 210:1021-1023 (1980). Centrella, "Transforming and Nontransforming Growth Fac-

tors are Present in Medium Conditioned by Fetal Rat Calvariae," Proc. Natl. Acad. Sci. USA 82:7335-7339 (1985).

(Continued)

Primary Examiner-Elizabeth Kemmerer (74) Attorney, Agent, or Firm-Kirkpatrick & Lockhart Nicholson Graham LLP

ABSTRACT

Disclosed are 1) osteogenic devices comprising a matrix containing osteogenic protein and methods of inducing endochondral bone growth in mammals using the devices; 2) amino acid sequence data, amino acid composition, solubility properties, structural features, homologies and various other data characterizing osteogenic proteins, 3) methods of producing osteogenic proteins using recombinant DNA technology, and 4) osteogenically and chondrogenically active synthetic protein constructs.

9 Claims, 30 Drawing Sheets



07/621,988

OSTEOGENIC PROTEINS

11-04-2008::11:20:48

Bib	liogr	aph	ic D)ata

Application Number: 07/621,988

Filing or 371 (c) 12-04-1990 Date:

Application Type: Utility NUTTER, NATHAN M

Examiner Name:

Group Art Unit: 1503 Confirmation

Number: Attorney Docket

Number:

CRP-001CP2DV Class / Subclass: 530/326 HERMANN OPPERMANN,

4207

MEDWAY, MA (US)

First Named Inventor: Title of Invention: Customer Number:

Status:

Abandoned -- File-Wrapper-Continuation Parent Application 01-15-1993

Status Date: Location:

Location Date: 03-16-1993 Earliest

Publication No: Earliest

Publication Date: Patent Number: Issue Date of

Patent:

OSTEOGENIC PROTEINS

Close Window



OSTEOGENIC PROTEINS

11-04-2008::11:20:13

Parent Continuity Data

Parent Number	Parent Filing or 371(c) Date	Parent Status	Patent Number
07/621,988	12-04-1990	Abandoned	_
07/315,342	02-23-1989	Patented	5,011,691
07/232,630	08-15-1988	Pending	
07/179,406	04-08-1988	Patented	4,968,590
	Number 07/621,988 07/315,342 07/232,630	Number Date 07/621,988 12-04-1990 07/315,342 02-23-1989 07/232,630 08-15-1988	Number Date Status 07/621,988 12-04-1990 Abandoned 07/315,342 02-23-1989 Patented 07/232,630 08-15-1988 Pending

Child Continuity Data

08/376,731 filed on 01-20-1995 which is Patented claims the benefit of 07/995,345 08/375,901 filed on 01-20-1995 which is Patented claims the benefit of 07/995,345 08/145,812 filed on 11-01-1993 which is Patented claims the benefit of 07/995,345 08/417,071 filed on 04-04-1995 which is Patented claims the benefit of 07/995,345 08/417,071 filed on 04-04-1995 which is Patented claims the benefit of 07/995,345 11/331,855 filed on 01-13-2006 which is Patented claims the benefit of 07/995,345 08/449,699 filed on 05-24-1995 which is Patented claims the benefit of 07/995,345 08/920,030 filed on 08-26-1997 which is Abandoned claims the benefit of 07/995,345 09/073,080 filed on 08-26-1997 which is Abandoned claims the benefit of 07/995,345 09/754,831 filed on 01-03-2001 which is Patented claims the benefit of 07/995,345 09/955,582 filed on 09-19-2001 which is Patented claims the benefit of 07/995,345 08/957,425 filed on 01-02-2003 which is Abandoned claims the benefit of 07/995,345 08/957,425 filed on 01-02-2003 which is Abandoned claims the benefit of 07/995,345 10/335,965 field on 01-02-2003 which is Abandoned claims the benefit of 07/995,345 12/195,617 filed on null which is Petenting claims the benefit of 07/995,345 12/195,617 filed on null which is Petenting claims the benefit of 07/995,345

Close Window